Pharmacodynamic study of Tianjiang xueshuantong pills in the treatment of coronary heart disease
- VernacularTitle:天降血栓通丸治疗冠心病的药效学研究
- Author:
Wenjie LI
1
;
Yingying LI
2
,
3
,
4
,
5
;
Jiang BIAN
2
,
3
,
4
,
5
;
Ting LIU
2
,
3
,
4
,
5
;
Yunxuan GUAN
2
,
3
,
4
,
5
;
Xibiao ZHANG
1
;
Shiliang ZHOU
1
;
Li SUN
1
;
Xi JIANG
2
,
3
,
4
Author Information
1. Tianjin Beichen Traditional Chinese Medical Hospital，Tianjin 300400，China
2. Tianjin Tiancheng Drug Assessment Co.，Ltd.，Tianjin 300462，China
3. Tianjin Key Laboratory of Pharmacokinetics and Pharmacodynamics，Tianjin 300462，China
4. Tianjin Engineering Research Center of Drug Preclinical Assessment Technology，Tianjin 300462，China
5. National Key Laboratory for Drug Formation Evaluation and System Transformation，Tianjin 300462，China
- Publication Type:Journal Article
- Keywords:
Tianjiang xueshuantong pills;
coronary heart disease;
acute myocardial ischemia;
hyperlipidemia;
platelet
- From:
China Pharmacy
2025;36(11):1358-1363
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To study the efficacy of Tianjiang xueshuantong pills in the treatment of coronary heart disease. METHODS In accordance with the common pathogenesis of coronary heart disease， acute myocardial ischemia model， hyperlipidemia model， blood stasis model， and carotid artery thrombosis model were established using Wistar rats or SD rats as the experimental subjects. The effects of Tianjiang xueshuantong pills administered at high， medium， and low doses （0.6， 1.2 and 2.4 g/kg） on hemodynamic parameters and myocardial enzyme markers [lactate dehydrogenase （LDH）， creatine kinase-MB （CK- MB）]， oxidative stress factors [superoxide dismutase （SOD）， malondialdehyde （MDA）， glutathione （GSH）]， inflammatory cytokines [tumor necrosis factor-α （TNF-α）， interleukin-6 （IL-6）， IL-1β， monocyte chemotactic protein-1 （MCP-1）， intercellular adhesion molecule-1 （ICAM-1）]， myocardial infarction percentage， serum lipid indexes [total cholesterol （TC）， triglycerides （TG）， low-density lipoprotein （LDL）， high-density lipoprotein （HDL）]， platelet aggregation function 话：022-84845240。E-mail：jiangx@tjipr.com [maximum aggregation rate （MAR）]， and thrombus formation indexes [thrombosis time， thrombus mass， thrombus protein content， plasminogen activator inhibitor-1 （PAI-1）， and tissue-type plasminogen activator （t-PA）] were evaluated in the rat models. RESULTS In myocardial ischemia tests， Tianjiang xueshuantong pills significantly reduced the percentage of myocardial infarction and the levels of CK-MB， LDH， MDA， GSH， IL-6， TNF-α， IL- 1β， and MCP-1 in serum （P＜0.05 or P＜0.01）. In hyperlipidemia tests， high dose of Tianjiang xueshuantong pills significantly reduced the serum levels of TC， LDL and significantly increased the level of HDL in rats after 2 weeks and 4 weeks of administration. In blood stasis tests， different doses of Tianjiang xueshuantong pills significantly reduced MAR of rats （P＜0.01）. In artery thrombosis tests， high dose of Tianjiang xueshuantong pills significantly prolonged the time of thrombosis formation （P＜ 0.01）， significantly reduced the weight and protein content of thrombus and the level of PAI-1 in serum （P＜0.01）. CONCLUSIONS Tianjiang xueshuantong pills exert therapeutic effects on coronary heart disease through multi-dimensional synergistic actions， including anti-myocardial ischemia， lipid-lowering， and anti-thrombotic effects.
